Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies

Rodrigo Cartin-Ceba, Michael Halank, Hossein Ardeschir Ghofrani, Marc Humbert, John Mattson, Arno Fritsch, Michael Joseph Krowka

Research output: Contribution to journalLetter

5 Scopus citations


In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.

Original languageEnglish (US)
JournalPulmonary Circulation
Issue number2
StatePublished - Apr 1 2018



  • portal hypertension
  • pulmonary arterial hypertension
  • soluble guanylate cyclase stimulator

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this